Ascendia

 

  MARKET NEWS

HCW Biologics & WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 IBS
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody Achieved 100% Virologic Response & Up To 78% Combined Virologic Response, & ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D
Quotient Sciences Announces Installation of World's First GMP Biofoundry-in-a-Box From Centillion Technology
AlveoGene Receives Rare Pediatric Disease Designation Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B Deficiency
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
Aravax Establishes Pharmaceutical Development Base on the Oxford Science Park With a Focus on Developing Manufacturing Capabilities in the UK

  EXPERT CONTENT & RESOURCES

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.

  FEATURED EDITORIAL

  COMPANY PROFILE

As a global leader in pharmaceutical and medical device testing, Element Materials Technology delivers comprehensive testing solutions that ensure product safety, quality, and regulatory compliance at every stage of development. From initial R&D through commercialization, our 150+ pharmaceutical experts worldwide bring over four decades of experience to your critical projects. Our expertise spans a comprehensive range of specialized capabilities including, but not limited to, biologics testing, Chemical, Manufacturing, and Controls (CMC), biocompatibility assessment, PFAS testing, extractables and leachables studies, and comprehensive antimicrobial and disinfectant analysis. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Mucoadhesion Matters

And so does your choice of mucoadhesive polymer.

This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 27 – Bioavailability
December 4 – Inhalation Delivery